Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution

Abstract

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

What is claimed is: 
     
         1 . A method of treating wounds comprising administering to a patient in need thereof a composition comprising substances dissolved in water, the substances comprising ascorbic acid, thiamine HCl, magnesium sulfate, cyanobalamin, a B-vitamin, pyridoxine HCl, riboflavin 5′-phosphate, calcium D-pantothenate, sodium bicarbonate, and sodium chloride. 
     
     
         2 . The method of  claim 1 , wherein the ascorbic acid is at a concentration from about 100 mg to about 500 mg, the thiamine is at a concentration from about 1 mg to about 100 mg, the magnesium sulfate is at a concentration from about 100 mg to about 500 mg, the cyanobalamin is at a concentration from about 100 .mu.g to about 500 .mu.g, the B-vitamin is at a concentration from about 1 mg to about 300 mg, the pyridoxine HCl is at a concentration from about 1 mg to about 100 mg, the riboflavin 5′-phosphate is at a concentration from about 1 mg to about 100 mg, and the calcium D-pantothenate is at a concentration from about 1 mg to about 100 mg. 
     
     
         3 . The method of  claim 1 , wherein the composition further comprises at least one of trace metals, 2 di-methyl amino ethanol HCl, lipoic acid, folic acid, an antibiotic, vitamins, vitamers, salts, acids, amino acids, an anesthetic, trace metals, and heparin. 
     
     
         4 . The method of  claim 3 , wherein the composition comprises the antibiotic. 
     
     
         5 . The method of  claim 4 , wherein the antibiotic is selected from the group consisting of erythromycin and gentamicin. 
     
     
         6 . The method of  claim 1 , wherein the composition further comprises vitamin K2. 
     
     
         7 . The method of  claim 1 , wherein the composition further comprises arginine. 
     
     
         8 . The method of  claim 1 , wherein the water is electroactivated water having an electrical potential of −200 to +800 with the substances dissolved therein. 
     
     
         9 . The method of  claim 8 , wherein the B-vitamin is niacinamide. 
     
     
         10 . The method of  claim 9 , wherein concentrations of the substances are 4.047% to 4.947% by weight ascorbic acid, 0.285% to 0.349% by weight thiamine HCl, 3.636% to 4.444% by weight magnesium sulfate, 0.0085% to 0.011% by weight cyanocobalamin, 0.5345% to 0.6535% by weight of niacinamide, 0.5345% to 0.6535% by weight pyridoxine HCl, 0.012% to 0.014% by weight riboflavin-5′-phosphate, 0.013% to 0.016% by weight calcium D-pantothenate, 2.10% to 6.30% by weight sodium bicarbonate, and 0.0009% to 0.0011% by weight sodium chloride. 
     
     
         11 . The method of  claim 10 , wherein concentrations of the substances are 4.4967% by weight ascorbic acid, 0.3167% by weight thiamine HCl, 4.040% by weight magnesium sulfate, 0.00965% by weight cyanocobalamin, 0.5940% by weight of niacinamide, 0.5940% by weight pyridoxine HCl, 0.0127% by weight riboflavin-5′-phosphate, 0.0147% by weight calcium D-pantothenate, 4.20% by weight sodium bicarbonate, and 0.001% by weight sodium chloride. 
     
     
         12 . The method of  claim 11 , wherein the water is water for injection (WFI) and the substances conform to USP quality standards. 
     
     
         13 . The method of  claim 1 , wherein the administering is by injection, oral administration, topical administration, transmucosal administration, or transdermal administration. 
     
     
         14 . A method of treating wounds comprising administering to a patient in need thereof a composition comprising the product of mixing contents of a first vial with contents of a second vial in a 1:1 ratio, the first vial containing an aqueous solution comprising ascorbic acid, thiamine HCl, magnesium sulfate, cyanocobalamin, a B-vitamin, pyridoxine HCl, riboflavin-5′-phosphate, calcium D-pantothenate, and sodium chloride; the second vial containing an aqueous solution comprising sodium bicarbonate, and sodium chloride, wherein the aqueous solution in the first vial has an electrical potential of +1000 to +1300 prior to mixing, and the aqueous solution in the second vial has an electrical potential of +5 to +700 prior to mixing, wherein the composition has an electrical potential of −1 to −200 after mixing. 
     
     
         15 . The method of  claim 14 , wherein the B-vitamin is a form of vitamin B3. 
     
     
         16 . The method of  claim 15 , wherein the form of vitamin B3 is niacinamide. 
     
     
         17 . The method of  claim 16 , wherein concentrations in the first vial are 8.094% to 9.893% by weight ascorbic acid, 0.570% to 0.697% by weight thiamine HCl, 7.272% to 8.888% by weight magnesium sulfate, 0.017% to 0.021% by weight cyanocobalamin, 1.069% to 1.307% by weight of niacinamide, 1.069% to 1.307% by weight pyridoxine HCl, 0.023% to 0.028% by weight riboflavin-5′-phosphate, 0.026% to 0.032% by weight calcium D-pantothenate, and 0.0009% to 0.0011% sodium chloride, and concentrations in the second vial are 4.20% to 12.60% by weight sodium bicarbonate, and 0.0009% to 0.0011% by weight sodium chloride. 
     
     
         18 . The method of  claim 17 , wherein concentrations in the first vial are 8.9933% by weight ascorbic acid, 0.6333% by weight thiamine HCl, 8.080% by weight magnesium sulfate, 0.0193% by weight cyanocobalamin, 1.188% by weight of niacinamide, 1.188% by weight pyridoxine HCl, 0.0253% by weight riboflavin-5′-phosphate, 0.0293% by weight calcium D-pantothenate, and 0.001% sodium chloride, and concentrations in the second are 8.40% by weight sodium bicarbonate, and 0.001% by weight sodium chloride. 
     
     
         19 . The method of  claim 14 , wherein the administering is by injection, oral administration, topical administration, transmucosal administration, or transdermal administration. 
     
     
         20 . The method of  claim 19 , wherein the administering is the topical administration.